Vol 10, No 4 (2019)
Case report
Published online: 2020-04-23
Progressive multifocal leukoencephalopathy in patient with diffuse large B-cell lymphoma and acquired immunodeficiency syndrome
12
, 12, 12, 3, 4, 5, 12
, 12, 12, 3, 4, 5, 12
Hematologia 2019;10(4):184-196.
Abstract
Diffused large B-cell lymphoma (DLBCL) is an agressive and one of the most common lymphomas. The treatment of choice is R-CHOP (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone) immunochemotherapy. In some cases also radiotherapy is indicated. DLBCL and other non-Hodgkin lymphomas maybe an acquired immune deficiency syndrome defining condition in human immunodeficiency virus (HIV) infection, and therefore indication for testing for this virus. Not only HIV infection, but lymphoma as well as immunotherapy may lead to John Cunningham virus reactivation and development of the progressive multifocal leukoencephalopathy.
Keywords: progressive progressive multifocal leukoencephalopathyJohn Cunningham virusdiffuse large B-cell lymphomahuman immunodeficiency virus
References
- Chesters PM, Heritage J, McCance DJ. Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. J Infect Dis. 1983; 147(4): 676–684.
- Saribas AS, Ozdemir A, Lam C, et al. JC virus-induced progressive multifocal leukoencephalopathy. Future Virol. 2010; 5(3): 313–323.
- Gheuens S, Pierone G, Peeters P, et al. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry. 2010; 81(3): 247–254.
- Jensen PN, Major EO. A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region. J Neurovirol. 2001; 7(4): 280–287.
- Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009; 10(8): 816–824.
- Shah R, Bag AK, Chapman PR, et al. Imaging manifestations of progressive multifocal leukoencephalopathy. Clin Radiol. 2010; 65(6): 431–439.
- Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013; 80(15): 1430–1438.
- Piccinni C, Sacripanti C, Poluzzi E, et al. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. Eur J Clin Pharmacol. 2010; 66(2): 199–206.
- Rowland LP. Neurologia Merritta. Elsevier Urban & Partner, Wrocław 2004: 205–206.
- Kulma-Kreft M, Leśniewski-Kmak K, Zaucha J. Diagnostyka i leczenie postępującej wieloogniskowej leukoencefalopatii. Acta Haematol Pol. 2015; 46(4): 280–285.
- Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol. 2006; 60(2): 162–173.
- Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010; 9(4): 425–437.
- Sainz-de-la-Maza S, Casado JL, Pérez-Elías MJ, et al. Incidence and prognosis of immune reconstitution inflammatory syndrome in HIV-associated progressive multifocal leucoencephalopathy. Eur J Neurol. 2016; 23(5): 919–925.
- Cinque P, Koralnik IJ, Gerevini S, et al. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis. 2009; 9(10): 625–636.
- Engsig FN, Hansen ABE, Omland LH, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis. 2009; 199(1): 77–83.
- Plavina T, Subramanyam M, Bloomgren G, et al. The effect of plasma exchange on serum anti-JC virus antibodies. Mult Scler. 2013; 19(7): 912–919.
- Ramqvist T, Dalianis T. Immunotherapeutic polyoma and human papilloma virus-like particles. Immunotherapy. 2009; 1(2): 303–312.
